Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
China · Delayed Price · Currency is CNY 40.85
+1.47 (3.73%)
At close: Oct 28, 2026
SHE:301281 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,424 | 3,173 | 3,239 | 3,686 | - | - | |
Market Cap Growth | 29.11% | -2.04% | -12.13% | - | - | - |
Enterprise Value | 4,308 | 2,944 | 2,786 | 3,045 | - | - |
Last Close Price | 40.85 | 29.27 | 29.70 | 33.41 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 64.01 | 191.68 | 53.58 | 47.85 | - | - |
PS Ratio | 7.65 | 7.97 | 6.99 | 8.24 | - | - |
PB Ratio | 3.03 | 2.34 | 2.38 | 2.77 | - | - |
P/TBV Ratio | 3.51 | 2.56 | 2.59 | 2.87 | - | - |
P/OCF Ratio | 62.27 | 72.99 | - | 99.54 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 7.45 | 7.39 | 6.01 | 6.80 | - | - |
EV/EBITDA Ratio | 31.21 | 44.76 | 31.88 | 28.35 | - | - |
EV/EBIT Ratio | 48.00 | 162.50 | 68.73 | 52.07 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.15 | 0.08 | 0.03 | - | - | - |
Debt / EBITDA Ratio | 1.58 | 1.71 | 0.52 | - | - | - |
Net Debt / Equity Ratio | -0.08 | -0.18 | -0.28 | -0.51 | -0.29 | -0.15 |
Net Debt / EBITDA Ratio | -0.85 | -3.75 | -4.43 | -6.39 | -1.22 | -0.60 |
Net Debt / FCF Ratio | 7.23 | 2.64 | 1.08 | 20.72 | -1.76 | -2.07 |
Asset Turnover | 0.32 | 0.25 | 0.31 | 0.42 | 0.73 | 0.83 |
Inventory Turnover | 1.96 | 1.46 | 2.25 | 2.74 | 3.43 | 3.13 |
Quick Ratio | 1.73 | 2.78 | 4.64 | 6.86 | 1.91 | 1.00 |
Current Ratio | 2.18 | 3.71 | 5.77 | 7.91 | 2.62 | 1.84 |
Return on Equity (ROE) | 5.08% | 1.21% | 4.48% | 8.33% | 19.20% | 20.24% |
Return on Assets (ROA) | 3.14% | 0.70% | 1.68% | 3.45% | 9.18% | 10.15% |
Return on Invested Capital (ROIC) | 5.73% | 1.70% | 4.60% | 11.13% | 22.44% | 21.47% |
Return on Capital Employed (ROCE) | 5.60% | 1.20% | 2.80% | 4.30% | 16.30% | 18.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.56% | 0.52% | 1.87% | 2.09% | - | - |
FCF Yield | -0.37% | -2.95% | -11.02% | -0.90% | - | - |
Dividend Yield | 0.12% | 0.17% | 0.67% | 0.88% | - | - |
Payout Ratio | 15.37% | 149.94% | 53.87% | 40.16% | - | - |
Buyback Yield / Dilution | -2.21% | -2.23% | -6.49% | -24.38% | -0.53% | 0.47% |
Total Shareholder Return | -2.09% | -2.06% | -5.82% | -23.50% | -0.53% | 0.47% |